• 1
    Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 16778.
  • 2
    Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108(7): 11328.
  • 3
    Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology 2004; 64(Suppl. 6A): 26.
  • 4
    Sacco E, Bientinesi R. Mirabegron: a review of recent data and its prospects in the management of overactive bladder. Ther Adv Urol 2012; 4(6): 31524.
  • 5
    Pannek J. European Association of Urology. Guidelines on neurogenic lower urinary tract dysfunction, 2011. (accessed June 2011).
  • 6
    Thüroff JW, Abrams P, Andersson KE et al. EAU guidelines on urinary incontinence European. Eur Urol 2011; 59(3): 387400.
  • 7
    Chapple CR, Yamanishi T, Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 2002; 60(Suppl. 5A): 8289.
  • 8
    Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011; 7(12): CD005493.
  • 9
    Moore KM, Hirst G, Emery S, Turner A, Lucas M. A double blind, placebo controlled, randomised, cross over study of trigone specific injections of botulinum toxin B for treating patients with idiopathic detrusor overactivity refractory to other conservative treatments (Abstract number 209). Neurourol Urodyn 2009; 28(7): 8334.
  • 10
    Botox® Summary of Product Characteristics. Irvine CA: Allergan, 2013.
  • 11
    Karsenty G, Denys P, Amarenco G et al. Botulinum toxin A (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder: a systematic literature review. Eur Urol 2008; 53(2): 27587.
  • 12
    Brubaker L, Richter HE, Visco A et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008; 180(1): 21722.
  • 13
    Chapple C, Sievert KD, Macdiarmid S et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind placebo-controlled trial. Eur Urol 2013; 64(2): 24956.
  • 14
    Cruz F, Herschorn S, Aliotta P et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011; 60(4): 74250.
  • 15
    Denys P, Le Normand L, Ghout I et al.; VESITOX Study Group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012; 61(3): 5209.
  • 16
    Dmochowski R, Chapple C, Nitti VW et al. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010; 184(6): 241622.
  • 17
    Giannantoni A, Di Stasi SM, Stephen RL, Bini V, Costantini E, Porena M. Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study. J Urol 2004; 172(1): 2403.
  • 18
    Ginsberg D, Gousse A, Keppenne V et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012; 187(6): 21319.
  • 19
    Granese R, Adile G, Gugliotta G, Cucinella G, Saitta S, Adile B. Botox(®) for idiopathic overactive bladder: efficacy, duration and safety. Effectiveness of subsequent injection. Arch Gynecol Obstet 2012; 286(4): 9239.
  • 20
    Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol 2011; 185(6): 222935.
  • 21
    Kalsi V, Apostolidis A, Popat R, Gonzales G, Fowler CJ, Dasgupta P. Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006; 49(3): 52835.
  • 22
    King J, Neville J. A randomised, double-blind, placebo controlled trial of botulinum toxin type A injections for the treatment of refractory idiopathic detrusor overactivity. Int Urogynecol J Pelvic Floor Dysfunct 2007; 18(Suppl. 1): S77.
  • 23
    Kuo HC. Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006; 68(5): 9937.
  • 24
    Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007; 178(4 Pt 1): 135963.
  • 25
    Lucioni A, Rapp DE, Gong EM, Fedunok P, Bales GT. Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection. Can J Urol 2006; 13(5): 32915.
  • 26
    Nitti VW, Dmochowski R, Herschorn S et al.; OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013; 189(6): 218693.
  • 27
    Popat R, Apostolidis A, Kalsi V, Gonzales G, Fowler CJ, Dasgupta P. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005; 174(3): 9849.
  • 28
    Rapp DE, Lucioni A, Katz EE, O'Connor RC, Gerber GS, Bales GT. Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: an initial experience. Urol. 2004; 63(6): 10715.
  • 29
    Reitz A, Stöhrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004; 45(4): 5105.
  • 30
    Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results J Urol 2000; 164: 6927.
  • 31
    Schurch B, de Sèze M, Denys P et al. ; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005; 174(1): 196200.
  • 32
    Smith CP, Nishiguchi J, O'Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urol. 2005; 65: 3741.
  • 33
    Thavaseelan JT, Burns-Cox N, Jordan K, Trewhella J. Efficacy of botulinum toxin type A (BOTOX) in the management of the neurogenic bladder: a prospective, randomised, double blind, dose comparative trial – interim overview of results. Br J Urol 2005; 95(Suppl. 1):45.
  • 34
    Dasgupta P. Volume matters: bladder injections of botulinum toxin type A. Eur Urol 2012; 61(6): 11856.
  • 35
    O'Leary M, Dierich M. Botulinum toxin type A for the treatment of urinary tract dysfunction in neurological disorders. Urol Nurs. 2010; 30(4): 228234.
  • 36
    Karsenty G, Elzayat E, Delapparent T, St-Denis B, Lemieux MC, Corcos J. Botulinum toxin type a injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux. J Urol 2007; 177(3): 10114.
  • 37
    Mascarenhas F, Cocuzza M, Gomes CM, Leão N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn 2008; 27(4): 3114.
  • 38
    Manecksha RP, Cullen IM, Ahmad S et al. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur Urol 2012; 61(5): 92835.
  • 39
    Abdel-Meguid TA. Botulinum toxin-A injections into neurogenic overactive bladder – to include or exclude the trigone? A prospective, randomized, controlled trial. J Urol 2010; 184(6): 24238.
  • 40
    Pinto R, Lopes T, Frias B et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur Urol 2010; 58(3): 3605.
  • 41
    Karsenty G, Carsenac A, Boy S et al. Botulinum toxin A in the treatment of neurogenic detrusor overactivity incontinence – a prospective randomized study to compare 30 vs 10 injection sites. Eur Urol Suppl 2007; 6: 245.